Cocrystal Pharma
COCPCocrystal Pharma is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule antiviral therapeutics for serious and chronic RNA viral diseases.
Earnings
Next report
Nov 13, 2026 (in 2 months)Competitors
By market cap
Profile
Cocrystal Pharma is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule antiviral therapeutics for serious and chronic RNA viral diseases. The company utilizes a proprietary structure-based drug discovery platform, guided by Nobel Prize-winning expertise, to design direct-acting antivirals that target highly conserved regions of viral enzymes. Their core value proposition lies in creating broad-spectrum treatments with high barriers to drug resistance for infections including influenza, norovirus, and coronaviruses.
A clinical-stage innovator using a proprietary structure-based platform to target highly conserved viral regions, aiming for best-in-class broad-spectrum efficacy.
FAQ
- What is Cocrystal Pharma's market cap?
- Cocrystal Pharma (COCP) has a market capitalization of $22.0M and trades on NASDAQ.
- Who are Cocrystal Pharma's competitors?
- Cocrystal Pharma's key competitors include Gilead Sciences, Inc., Pfizer Inc., Moderna, Inc., and others. These companies compete in similar markets and product categories.
- Who does Cocrystal Pharma partner with?
- Cocrystal Pharma's notable partners include Merck & Co., Emory University School of Medicine.
- Where is Cocrystal Pharma headquartered?
- Cocrystal Pharma is headquartered in United States of America and employs approximately 12 people. It has been publicly traded since 2008.